Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	116.86M
Revenue (ttm)	351.41M
Net Income (ttm)	880,000
Shares Out	161.81M
EPS (ttm)	0.01
PE Ratio	130.57
Forward PE	4.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,930,905
Open	0.6130
Previous Close	0.6479
Day's Range	0.6100 - 0.7378
52-Week Range	0.5900 - 8.4500
Beta	0.30
Analysts	Buy
Price Target	4.94 (+584.02%)
Earnings Date	May 8, 2025

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 253
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://ironwoodpharma.com

Analyst Forecast

According to 5 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $4.94, which is an increase of 584.02% from the latest price.

Price Target

$4.94

(584.02% upside)

Analyst Consensus: Buy